Edit Entry | Edit CV

Richard I. Enelow, MD

Professor of Medicine
Professor of Microbiology and Immunology

Additional Titles/Positions/Affiliations
Vice-Chair for Research Affairs, Department of Medicine
Director, Interstitial Lung Disease Program

Microbiology and Immunology

BA Amherst College, 1978
MD Boston University, 1983.
Post-doctoral fellowship, Viral Immunology, University of Virginia, 1992-97

Immunology Program
Molecular and Cellular Biology Graduate Programs


Academic Analytics
View Profile

Contact Information

1 Medical Center Drive
Lebanon NH 03756

Office: DHMC 5C
Phone: (603) 650-5533
Fax: (603) 650-0580
Email: richard.i.enelow@dartmouth.edu

Assistant: Dana Landis
Asst. Phone: (603) 650-5533
Asst. Email: Dana.R.Landis@hitchcock.org

Professional Interests

Immunopathogenesis of respiratory virus infection;
Influenza pathogenesis;
Inflammatory and immune-mediated lung disease

Grant Information

R01AI069360 (PI: Enelow)
"TNF Processing in Pulmonary Immunopathology"

U19 AI83024 (PI: Enelow)
"Innate Regulation of CD8+ T Cell Effector Activities"

Courses Taught

Advanced Topics in Immunology
PEMM Immunology Module


My area of research broadly concerns the mechanisms that underlie the immune-mediated damage to the lungs which occurs in the context of respiratory virus infection. My clinical interests include immune-mediated lung disease, particularly the idiopathic interstitial pneumonias, and I have spent my entire career exploring the potential relationship between antiviral T cell responses to respiratory infection to chronic inflammatory lung disease. I became interested in host responses to pulmonary infection as a research fellow in Infectious Disease at the University of Virginia, while pursuing clinical training in Pulmonary Disease. I then spent the next 5 years as a post-doctoral fellow in the laboratory of Dr. Thomas J. Braciale, M.D., Ph.D., (Microbiology/Pathology), Director of the newly-established Beirne B. Carter Center for Immunology Research at the University of Virginia, in order to receive rigorous training in viral immunopathogenesis. Aside from outstanding training and mentoring in addressing questions in basic cellular and molecular immunology, I became fascile with the techniques necessary to work with and manipulate negative-strand RNA viruses, such as influenza and RSV, and these respiratory infections have been the focus of most of my work after moving to Yale, and then to Dartmouth. I have extensive experience in mouse and human basic immunology, and my laboratory is currently home to 2 junior faculty members, 3 postdoctoral fellows, 1 graduate student, and 2 research assistants, so I have ample capacity to take on a variety of collaborative projects in addition to our primary areas of exploration. In addition I have 20 years of experience participating in multi-investigator clinical trials, in interstitial lung disease (particularly idiopathic pulmonary fibrosis), my clinical area of interest, and several publications which have come from these endeavors. For information on the Clinical Research Program in Interstitial Lung Disease see http://www.dartmouth.edu/~renelowlab/the-dartmouth-interstitial.html

Selected Publications


Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.
Raghu G, Richeldi L, Fernandez Perez ER, De Salvo MC, Silva RS, Song JW, Ogura T, Xu ZJ, Belloli EA, Zhang X, Seid LL, Poole L, ZEPHYRUS-1 Study Investigators
JAMA. 2024 May 19; doi: 10.1001/jama.2024.8693. Epub 2024 May 19.
PMID: 38762797

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS, ISABELA 1 and 2 Investigators
JAMA. 2023 May 9;329(18):1567-1578. doi: 10.1001/jama.2023.5355.
PMID: 37159034

Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.
Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, Dilling DF, Criner GJ, Kim H, Belloli EA, Nambiar AM, Scholand MB, Anstrom KJ, Noth I, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative
JAMA. 2021 May 11;325(18):1841-1851. doi: 10.1001/jama.2021.4956.
PMID: 33974018

Single-cell RNA-seq Analysis Reveals That Prenatal Arsenic Exposure Results in Long-term, Adverse Effects on Immune Gene Expression in Response to Influenza A Infection.
Hsu KS, Goodale BC, Ely KH, Hampton TH, Stanton BA, Enelow RI
Toxicol Sci. 2020 Aug 1;176(2):312-328. doi: 10.1093/toxsci/kfaa080.
PMID: 32514536

STAT2 Signaling Regulates Macrophage Phenotype During Influenza and Bacterial Super-Infection.
Gopal R, Lee B, McHugh KJ, Rich HE, Ramanan K, Mandalapu S, Clay ME, Seger PJ, Enelow RI, Manni ML, Robinson KM, Rangel-Moreno J, Alcorn JF
Front Immunol. 2018;9:2151. doi: 10.3389/fimmu.2018.02151. Epub 2018 Sep 25.
PMID: 30337919

Volatile fingerprinting of human respiratory viruses from cell culture.
Purcaro G, Rees CA, Wieland-Alter WF, Schneider MJ, Wang X, Stefanuto PH, Wright PF, Enelow RI, Hill JE
J Breath Res. 2018 Mar 1;12(2):026015. doi: 10.1088/1752-7163/aa9eef. Epub 2018 Mar 1.
PMID: 29199638

Infant Infections and Respiratory Symptoms in Relation to in Utero Arsenic Exposure in a U.S. Cohort.
Farzan SF, Li Z, Korrick SA, Spiegelman D, Enelow R, Nadeau K, Baker E, Karagas MR
Environ Health Perspect. 2016 Jun;124(6):840-7. doi: 10.1289/ehp.1409282. Epub 2015 Sep 11.
PMID: 26359651

Shedding of TNF receptor 2 by effector CD8⁺ T cells by ADAM17 is important for regulating TNF-α availability during influenza infection.
DeBerge MP, Ely KH, Wright PF, Thorp EB, Enelow RI
J Leukoc Biol. 2015 Sep;98(3):423-34. doi: 10.1189/jlb.3A0914-432RR. Epub 2015 May 27.
PMID: 26019295

Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice.
Lee B, Robinson KM, McHugh KJ, Scheller EV, Mandalapu S, Chen C, Di YP, Clay ME, Enelow RI, Dubin PJ, Alcorn JF
Am J Physiol Lung Cell Mol Physiol. 2015 Jul 15;309(2):L158-67. doi: 10.1152/ajplung.00338.2014. Epub 2015 May 22.
PMID: 26001778

The role of IL-27 in susceptibility to post-influenza Staphylococcus aureus pneumonia.
Robinson KM, Lee B, Scheller EV, Mandalapu S, Enelow RI, Kolls JK, Alcorn JF
Respir Res. 2015 Feb 5;16(1):10. doi: 10.1186/s12931-015-0168-8. Epub 2015 Feb 5.
PMID: 25651926

View more publications on PubMed